Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

By Monk Bradley J.   Lammers Philip E.   Cartwright Thomas   Jacobs Ira  

Pharmaceuticals, Vol. 10, Iss. 1, 2017-01 ,pp. : 19-19

MDPI

Access to resources Recommend Favorite

Campylobacter jejuni Fatal Sepsis in a Patient with Non-Hodgkin’s Lymphoma: Case Report and Literature Review of a Difficult Diagnosis

By Gallo Maria Teresa   Di Domenico Enea Gino   Toma Luigi   Marchesi Francesco   Pelagalli Lorella   Manghisi Nicola   Ascenzioni Fiorentina   Prignano Grazia   Mengarelli Andrea   Ensoli Fabrizio  

International Journal of Molecular Sciences, Vol. 17, Iss. 4, 2016-04 ,pp. : 544-544

MDPI

Access to resources Recommend Favorite

Non-Coding RNAs in Hodgkin Lymphoma

By Cordeiro Anna   Monzó Mariano   Navarro Alfons  

International Journal of Molecular Sciences, Vol. 18, Iss. 6, 2017-05 ,pp. : 1154-1154

MDPI

Access to resources Recommend Favorite

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

By Lammers Philip   Criscitiello Carmen   Curigliano Giuseppe   Jacobs Ira  

Pharmaceuticals, Vol. 7, Iss. 9, 2014-09 ,pp. : 943-953

MDPI

Access to resources Recommend Favorite

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy

By Grover Natalie S.   Park Steven I.  

Pharmaceuticals, Vol. 8, Iss. 3, 2015-09 ,pp. : 607-636

MDPI

Access to resources Recommend Favorite